📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-30 11:07
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
29% Revenue Growth and ₹2,000 Cr FY27 Capex Guidance Highlight Q1 FY27 Performance
Laurus Labs reported a strong Q1 FY27 with revenue growing 29% YoY to ₹2,026 cr, primarily driven by a 69% surge in the CDMO segment. EBITDA margins expanded significantly to 31.8%, up 700 bps from the previous quarter, reflecting improved capacity utilization and a favorable product mix. Management has aggressively increased its FY27 capex guidance to ₹2,000 cr (approx. 29% of TTM revenue) to meet rising customer demand. Strategic advancements include a new ADC molecule agreement and the final stages of acquiring a 500-acre land parcel for future expansion.
Confidence: HIGH
What changedThe company has significantly accelerated its CDMO business and nearly doubled its annual capex guidance to support high demand for complex molecules.
Why it mattersThe shift towards high-margin CDMO and complex technology platforms (ADCs, Peptides) is structurally improving the company's profitability and reducing its dependence on the volatile generics market.
Q1 Revenue: ₹2,026 crCDMO Revenue Growth (YoY): 69%EBITDA Margin: 31.8%FY27 Capex Guidance: ₹2,000 crCapex vs TTM Revenue: ~29.3%Net Debt: ₹2,656 cr
📅 Short termThe sharp margin recovery and strong CDMO performance are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe aggressive capacity expansion and focus on complex modalities like ADCs and gene therapy position the company for a higher growth trajectory over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk on large-scale capex
- Rising debt levels (₹2,656 cr)
- Clinical-stage risks for new ADC molecules
Key Highlights
CDMO segment revenue grew 69% YoY to ₹835 cr, with 55% of this coming from commercial supplies.
EBITDA margins reached 31.8%, representing a 7 percentage point expansion over the previous quarter.
FY27 capex guidance was revised upward to ₹2,000 cr, nearly doubling from initial estimates of ₹1,000 cr.
R&D spending increased 70% YoY to 5.8% of revenue, focusing on complex technologies like ADCs and gene therapy.
Laurus Bio Phase 1 fermentation capacity of 400+ kiloliters is expected to be operational by the end of 2026.
👀 What to Watch
Monitor the execution timeline of the ₹2,000 cr capex plan and the operationalization of the new fermentation capacity at Laurus Bio by year-end. Watch for continued margin stability above 30% as the CDMO mix increases.
126% PAT Growth: Laurus Labs Reports Strong Q1 FY27 with ₹2,026 Cr Revenue
Laurus Labs delivered a robust Q1 FY27 with revenue growing 29% YoY to ₹2,026 Cr, driven primarily by a 67% surge in the high-margin CDMO segment. Net profit jumped 126% to ₹368 Cr, while EBITDA margins expanded significantly by 700 bps to 31.8% due to better capacity utilization and segment mix. The company continues its aggressive expansion, investing 19% of sales into CAPEX and in-licensing two Antibody Drug Conjugate (ADC) assets for the Indian market.
Confidence: HIGH
What changedLaurus Labs has successfully shifted its revenue mix toward high-margin CDMO services, which now contribute significantly to the bottom line, alongside a major margin expansion from 24.8% to 31.8%.
Why it mattersThe results validate the company's transition from a generic API player to a diversified CDMO and specialty biotech firm, which typically commands higher valuations and offers more stable long-term growth.
Q1 Revenue: ₹2,026 CrYoY PAT Growth: 126%EBITDA Margin: 31.8%CDMO Revenue Growth: 67%Capex as % of Sales: 19%Q1 Revenue vs TTM Revenue: 29.7%
📅 Short termThe stock is likely to react positively to the sharp margin expansion and the significant beat in net profit compared to previous quarters.
📈 Long termThe structural shift towards CDMO, Biologics, and ADCs, supported by heavy ongoing CAPEX, positions the company for sustained growth over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High CAPEX and R&D intensity may pressure short-term cash flows
- Global supply chain volatility
- Regulatory risks associated with USFDA audits
Key Highlights
Revenue reached ₹2,026 Cr, a 29% YoY increase from ₹1,570 Cr in Q1 FY26
CDMO segment revenue grew 67% YoY to ₹870 Cr, driven by late-stage clinical and commercial API supplies
EBITDA margins expanded to 31.8% from 24.8% in the previous year's quarter
Net Profit surged 126% YoY to ₹368 Cr compared to ₹163 Cr in Q1 FY26
R&D investment increased 74% YoY to ₹118 Cr, representing 5.8% of total revenue
👀 What to Watch
Monitor the commissioning of the new fermentation facility expected in Q3 FY27 and the progress of the KRKA JV production blocks scheduled for mid-2027. Investors should track the execution of the 125+ active CDMO projects as they transition to commercial stages.
29% Revenue Growth and 126% PAT Surge in Q1 FY27; CDMO Segment Up 67%
Laurus Labs reported a strong Q1 FY27 with revenue reaching ₹2,026 Cr, a 29% YoY increase driven by a 67% surge in the high-margin CDMO segment. EBITDA margins expanded significantly by 700 bps to 31.8%, resulting in a 126% jump in Net Profit to ₹368 Cr. The company continues its aggressive expansion with Q1 capex of ₹394 Cr (19% of revenue) as part of a larger ₹4,700+ Cr multi-year investment plan. Operational highlights include the operationalization of a second CAR-T cell therapy facility and progress in Antibody Drug Conjugates (ADC).
Confidence: HIGH
What changedSignificant shift in product mix towards high-margin CDMO (43% of revenue) and a sharp recovery in profitability margins compared to the previous fiscal year.
Why it mattersThe transition from a generic API player to a CDMO and Biologics-led business is materializing in the financial results, reducing reliance on the volatile ARV market and improving return profiles.
Q1 Revenue: ₹2,026 CrCDMO Revenue Growth (YoY): 67%EBITDA Margin: 31.8%Q1 Capex vs TTM Revenue: ~5.8%Net Debt-to-EBITDA: 1.3xR&D Spend (% of Revenue): 5.8%
📅 Short termPositive market reaction is likely due to the strong margin expansion and robust growth in the CDMO division, which exceeded historical averages.
📈 Long termStructural shift towards CDMO and Biologics (ADC, Gene Therapy) provides a higher-margin, more sustainable growth profile as new capacities come online through FY27.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High capex intensity (19% of sales) may pressure free cash flows
- Execution risks in complex biologics and ADC platforms
Key Highlights
Revenue grew 29% YoY to ₹2,026 Cr, driven by robust CDMO growth and steady affordable medicine sales.
CDMO segment revenue increased 67% YoY to ₹870 Cr, now contributing 43% of total revenue compared to 33% a year ago.
EBITDA margins improved to 31.8% from 24.8% YoY, aided by a favorable product mix and operational leverage.
Quarterly Capex stood at ₹394 Cr, representing 19% of the quarter's revenue, focused on API and Advanced Biologics.
Net Profit surged 126% YoY to ₹368 Cr, with EPS rising to ₹6.8 from ₹3.0 in Q1 FY26.
👀 What to Watch
Monitor the execution of the ₹4,700+ Cr capex plan and the ramp-up of the new Advanced Biologics facilities in Navi Mumbai and Vizag scheduled for late 2026/2027.
Laurus Labs Q1 Net Profit Jumps 124% YoY to ₹362 Cr; Revenue Up 29%
Laurus Labs reported a strong start to FY27, with consolidated revenue growing 29.1% YoY to ₹2,026.31 Cr. Net profit more than doubled to ₹362.07 Cr from ₹161.68 Cr in the year-ago period, reflecting significant margin expansion. The company's operating efficiency improved as total expenses grew by only 14.6% despite the 29% revenue surge. This performance suggests a strong recovery and potential scale-up in high-margin segments like CDMO.
Confidence: HIGH
What changedLaurus Labs has reported a sharp turnaround in profitability and revenue growth for Q1 FY27 compared to the relatively subdued performance in early FY26.
Why it mattersThe significant jump in margins and profit suggests that the company's investments in CDMO and specialized APIs are beginning to yield higher returns, potentially re-rating the stock if sustained.
Revenue (Q1 FY27): ₹2,026.31 CrNet Profit (Q1 FY27): ₹362.07 CrYoY Revenue Growth: 29.1%YoY Net Profit Growth: 124.0%EPS (Basic): ₹6.81
📅 Short termThe stock is likely to react positively in the short term due to the substantial profit beat and margin improvement over previous quarters.
📈 Long termThe structural shift towards CDMO and Bio-ingredients, coupled with the upcoming ADC technology platform, supports a positive long-term outlook if execution remains on track.
⚠ Risk flags
- Regulatory risks from USFDA inspections
- Execution delays in high-margin CDMO contracts
- Pending NCLT approval for internal restructuring
Key Highlights
Consolidated revenue from operations increased 29.1% YoY to ₹2,026.31 Cr from ₹1,569.57 Cr.
Net profit after tax surged 124% YoY to ₹362.07 Cr compared to ₹161.68 Cr in Q1 FY26.
Earnings Per Share (EPS) rose to ₹6.81 from ₹3.02 in the corresponding quarter of the previous year.
Total expenses as a percentage of revenue dropped to 76.7% from 86.4% YoY, indicating improved operational leverage.
Allotted 393,001 equity shares during the quarter following the exercise of employee stock options.
👀 What to Watch
Monitor the execution of the CDMO segment and the timeline for the Laurus Bio capacity expansion expected by late 2026. Investors should also track the NCLT approval process for the merger of Laurus Synthesis Private Limited.
Laurus Labs to Hold 21st AGM on July 2, 2026; Proposes ₹2.00 Total Dividend Ratification
Laurus Labs has scheduled its 21st Annual General Meeting (AGM) for July 2, 2026, to be conducted via video conferencing. Shareholders will vote on the ratification of two interim dividends paid during FY 2025-26, totaling ₹2.00 per equity share. The agenda also includes the appointment of two new Independent Directors, Dr. Shekhar Chintamani Mande and Mrs. Sutapa Banerjee, for five-year terms. Additionally, the company seeks approval for Non-Executive Director remuneration capped at 1% of net profits.
Key Highlights
AGM scheduled for July 2, 2026, with the e-voting period running from June 29 to July 1, 2026.
Ratification of 1st interim dividend (₹0.80) and 2nd interim dividend (₹1.20) per share for FY 2025-26.
Proposed appointment of Dr. Shekhar Chintamani Mande and Mrs. Sutapa Banerjee as Independent Directors for a 5-year term.
Approval sought for Non-Executive Director remuneration aggregating to a maximum of 1% of annual net profits.
Re-appointment of retiring directors Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava.
👀 What to Watch
Investors should participate in the e-voting process starting June 29 to exercise their rights on director appointments and remuneration policies. Since the dividends are ratifications of previously paid amounts, no immediate impact on cash flow is expected.
Laurus Labs Joins Dow Jones Best-in-Class World Index; ESG Score Rises to 81
Laurus Labs has achieved a significant milestone by being included in the Dow Jones Best-in-Class (DJ BIC) World Index for the first time. This inclusion is driven by a substantial improvement in the company's S&P Global Corporate Sustainability Assessment (CSA) score, which rose to 81 out of 100 from 71 in the previous year. The recognition highlights the company's commitment to ESG parameters and places it among global leaders in the pharmaceutical sector. This development is expected to enhance the company's credibility and attractiveness to global institutional investors and ESG-focused funds.
Key Highlights
First-time inclusion in the prestigious Dow Jones Best-in-Class (DJ BIC) World Index.
S&P Global CSA score improved significantly to 81/100, up from 71/100 in the previous year.
Previously featured in the S&P Global Sustainability Yearbook 2026 for strong ESG performance.
The inclusion recognizes the company's commitment to sustainable and ethical corporate governance practices.
👀 What to Watch
Investors should consider this a positive qualitative development that strengthens the company's institutional appeal. This may lead to increased interest from ESG-mandated global funds, potentially supporting the stock's long-term valuation.
Laurus Labs FY26 Revenue Up 23% to INR 6,813 Cr; PAT Surges 148% on CDMO Growth
Laurus Labs delivered a robust FY26 performance with total revenue reaching INR 6,813 crores, driven by a 38% growth in the small molecule CDMO segment. The company's EBITDA margin expanded significantly by 6.7 percentage points to 26.8%, while Profit After Tax (PAT) surged by 148% to INR 889 crores. Strategic diversification is evident as the CDMO share rose to over 30% of total revenue, reducing dependence on the ARV segment to 41%. The company continues its aggressive expansion with a full-year capex of INR 1,070 crores focused on high-growth modalities like peptides and fermentation.
Key Highlights
FY26 Revenue grew 23% YoY to INR 6,813 crores, with Q4 EBITDA margins reaching a high of 28.9%.
Small molecule CDMO business crossed the INR 2,000 crore mark, growing 38% driven by late-stage pipeline programs.
Full-year PAT increased by 148% to INR 889 crores, supported by strong operating leverage and a better product mix.
Invested INR 1,070 crores in capex during FY26, with over 75% dedicated to expanding CDMO and CMO capabilities.
Financial health improved with Net Debt to EBITDA falling to 1.25x from 2.3x in the previous year.
👀 What to Watch
Investors should focus on the successful transition toward a CDMO-heavy model and the upcoming commissioning of the Vizag fermentation and Unit 7 facilities. The significant improvement in debt-to-EBITDA levels provides a comfortable cushion for ongoing large-scale capital expenditure.
Laurus Labs Appoints Two New Independent Directors for 5-Year Terms Starting July 2026
Laurus Labs has announced the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for five-year terms starting July 02, 2026. Dr. Mande is a distinguished scientist and former Director General of CSIR, while Ms. Banerjee brings over 30 years of experience in global financial services and wealth management. These appointments coincide with the retirement of Mrs. Aruna Bhinge, who will complete her second term on July 06, 2026. The addition of high-caliber experts from scientific and financial domains is expected to strengthen the board's strategic oversight.
Key Highlights
Dr. Shekhar Chintamani Mande appointed as Independent Director for a 5-year term effective July 02, 2026.
Ms. Sutapa Banerjee appointed as Independent Director for a 5-year term effective July 02, 2026.
Mrs. Aruna Bhinge to retire on July 06, 2026, after completing two full terms as an Independent Director.
New directors bring expertise from the Council of Scientific and Industrial Research (CSIR) and major banks like ANZ Grindlays and ABN AMRO.
👀 What to Watch
Investors should view these appointments as a positive step toward enhancing corporate governance and technical expertise at the board level. No immediate action is required as these changes are part of routine board succession planning.
Laurus Labs to Invest EUR 9.8 Million in KRKA Pharma JV for New Manufacturing Facility
Laurus Labs has approved an additional investment of up to EUR 9.8 million in its joint venture, KRKA Pharma Private Limited. The Slovenian co-venturer, KRKA d.d., will also invest approximately EUR 10.2 million, maintaining the existing 49:51 shareholding ratio. These funds are specifically designated for capital expenditure to establish a new manufacturing facility in India. The JV, incorporated in 2024, is currently providing R&D services and reported a turnover of INR 10.47 million in FY26.
Key Highlights
Laurus Labs to invest up to EUR 9.8 million (approx. INR 88-90 Cr) in KRKA Pharma JV
Co-venturer KRKA d.d. Slovenia to invest EUR 10.2 million to maintain 51% stake
Investment proceeds will be used for setting up a new manufacturing facility
Laurus Labs will maintain its 49% equity stake in the joint venture
The investment is scheduled to be completed during the financial year 2026-27
👀 What to Watch
This expansion signals a commitment to long-term growth and capacity building in partnership with a global pharma player. Investors should view this as a positive strategic move, though the financial benefits will only materialize once the new facility becomes operational.
Laurus Labs Appoints Dr. Shekhar Mande and Ms. Sutapa Banerjee as Independent Directors
Laurus Labs has announced the appointment of two high-profile Independent Directors, Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee, for five-year terms starting July 2, 2026. Dr. Mande is a renowned scientist and former Director General of CSIR, while Ms. Banerjee is a veteran in financial services and wealth management. These appointments follow the scheduled retirement of Mrs. Aruna Bhinge on July 6, 2026, after a 10-year tenure. The inclusion of such experts is expected to bolster the company's strategic oversight in R&D and financial governance.
Key Highlights
Dr. Shekhar Chintamani Mande appointed as Independent Director for a 5-year term starting July 2, 2026.
Ms. Sutapa Banerjee appointed as Independent Director for a 5-year term starting July 2, 2026.
Mrs. Aruna Bhinge to retire on July 6, 2026, after completing two consecutive 5-year terms.
New directors bring significant expertise from CSIR (scientific research) and top-tier banking/wealth management.
👀 What to Watch
The addition of a top scientist and a finance veteran to the board strengthens corporate governance and strategic depth. Investors should view this as a positive development for the company's long-term oversight.
Laurus Labs Declares 2nd Interim Dividend of Rs 1.20 per Share; Record Date May 08
Laurus Labs has approved a second interim dividend of Rs 1.20 per equity share for the financial year 2025-26, which represents 60% of the face value of Rs 2. The company has designated May 08, 2026, as the record date to identify eligible shareholders for this distribution. The dividend is scheduled to be paid to shareholders on or after May 20, 2026. This move reflects the company's continued commitment to returning value to its shareholders during the fiscal year.
Key Highlights
Approved 2nd interim dividend of Rs 1.20 per equity share for FY 2025-26
Dividend payout represents 60% of the face value of Rs 2 per share
Record date for determining shareholder eligibility is fixed as May 08, 2026
Dividend payment will be processed on or after May 20, 2026
👀 What to Watch
Investors looking to benefit from this dividend should ensure they hold the stock before the ex-dividend date, which is typically one business day before the May 08 record date. Long-term investors should monitor the company's overall payout ratio and earnings growth to assess dividend sustainability.
Laurus Labs FY26 Net Profit Jumps 148% to ₹889 Cr; EBITDA Margins Expand to 26.8%
Laurus Labs reported a robust performance for FY26, with annual revenue growing 23% to ₹6,813 crore and net profit surging 148% to ₹889 crore. The growth was primarily driven by a 38% increase in the CDMO Small Molecules segment and an 18% rise in the Affordable Medicines division. EBITDA margins saw a significant expansion of 670 basis points to 26.8%, aided by a favorable product mix and operating leverage. The company also declared a second interim dividend of ₹1.2 per share and signaled increased CAPEX intensity for FY27-28 to support new technology platforms.
Key Highlights
Full-year FY26 Net Profit grew 148% YoY to ₹889 crore, with Q4 profit rising 19% to ₹279 crore.
EBITDA margins improved significantly by 6.7% points to 26.8% for FY26, supported by a 60.4% gross margin.
CDMO Small Molecules segment revenue grew 38% in FY26 to ₹1,896 crore, backed by 125+ active projects.
FY26 CAPEX stood at 16% of sales, with planned increases for FY27-28 in Peptides and Gene therapy.
Declared a second interim dividend of ₹1.2 per share during the fourth quarter.
👀 What to Watch
Investors should note the significant margin recovery and the scaling CDMO business which is diversifying revenue away from the volatile ARV segment. The aggressive CAPEX plan for high-value technologies like ADCs and Peptides positions the company for long-term growth despite short-term capital intensity.
Laurus Labs FY26 Net Profit Surges 148% to ₹889 Cr; CDMO Revenue Grows 36%
Laurus Labs reported a robust performance for FY26, with total revenues growing 23% to ₹6,813 crore, driven by a 36% surge in the CDMO segment. Net profit witnessed a massive 148% increase to ₹889 crore, supported by a significant expansion in EBITDA margins to 26.8% from 20.1% in the previous year. The company is successfully de-risking its portfolio by reducing dependence on ARV APIs and increasing its high-margin CDMO and generic FDF contributions. With a ₹1,070 crore capex in FY26 and a long-term $600 million investment plan for a new Vizag site, the company is positioning itself for sustained high-tech pharmaceutical growth.
Key Highlights
FY26 Revenue grew 23% YoY to ₹6,813 Cr, with CDMO segment contributing 31% of total revenue mix.
Net Profit jumped 148% to ₹889 Cr, while EBITDA margins expanded by 670 bps to 26.8%.
Net Debt-to-EBITDA significantly improved to 1.3x from 2.3x in the previous year due to better cash flows.
Company executed ₹1,070 Cr in Capex during FY26, focusing on ADC, Gene Therapy, and Peptides.
ROCE nearly doubled to 17.7% in FY26 compared to 9.7% in FY25, reflecting improved operating leverage.
👀 What to Watch
Investors should view the strong margin recovery and the strategic shift towards the high-growth CDMO segment as positive long-term catalysts. The significant reduction in leverage and improved ROCE suggest the company's heavy investment phase is beginning to yield high-quality returns.
Laurus Labs to Invest €9.8M in KRKA JV for Capex; Appoints New Independent Directors
Laurus Labs has approved an investment of up to €9.8 million in its joint venture, KRKA Pharma Private Limited, to fund the construction of a new manufacturing facility. The co-venturer, KRKA d.d., will also invest €10.2 million, ensuring the 51:49 shareholding ratio remains unchanged. Simultaneously, the company is strengthening its board by appointing Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors. The board also approved the closure of its non-operational German subsidiary, which had zero revenue in FY26, to streamline operations.
Key Highlights
Investment of up to €9.8 million in KRKA Pharma JV to fund a new manufacturing plant.
JV partner KRKA d.d. to invest €10.2 million, maintaining Laurus Labs' 49% stake.
Appointment of Dr. Shekhar Mande (ex-DG, CSIR) and Ms. Sutapa Banerjee as Independent Directors for 5-year terms.
Voluntary closure of Laurus Generics GmbH (Germany) which reported zero turnover in FY26.
KRKA Pharma JV reported a turnover of INR 10.47 million in FY26 during its R&D phase.
👀 What to Watch
Investors should view the JV investment as a positive step toward long-term capacity expansion and strategic growth. The addition of high-profile independent directors further strengthens corporate governance and technical oversight.
Laurus Labs FY26 Net Profit Surges 151% to ₹890 Cr; Declares ₹1.20 Interim Dividend
Laurus Labs reported a robust financial performance for the fiscal year ended March 31, 2026, with annual consolidated revenue growing 23% to ₹6,812.90 crore. The company's net profit for FY26 saw a massive jump of 151%, reaching ₹889.85 crore compared to ₹354.41 crore in the previous year. For the fourth quarter alone, net profit stood at ₹281.91 crore, nearly a four-fold increase from the ₹73.45 crore reported in Q4 FY25. Additionally, the board has approved a second interim dividend of ₹1.20 per share, rewarding shareholders for the strong performance.
Key Highlights
Annual Consolidated Revenue increased by 22.7% YoY to ₹6,812.90 crore in FY26.
Full-year Net Profit grew by 151% YoY to ₹889.85 crore from ₹354.41 crore in FY25.
Q4 FY26 Net Profit rose to ₹281.91 crore, a significant jump from ₹73.45 crore in the year-ago quarter.
Declared a 2nd interim dividend of ₹1.20 per share (60% of face value) with a record date of May 08, 2026.
Earnings Per Share (EPS) for FY26 improved significantly to ₹16.47 from ₹6.65 in the previous fiscal.
👀 What to Watch
The significant turnaround in profitability and strong revenue growth indicate that the company's expansion and operational strategies are yielding high returns. Investors should consider holding the stock as the company demonstrates strong operational leverage and consistent dividend payouts.
Laurus Labs Clarifies Filing Lapses; Reports Strong Q2 FY26 Net Profit of ₹194.49 Cr
Laurus Labs has responded to NSE's clarification request regarding technical discrepancies in its September 2025 financial filings, attributing them to portal glitches and inadvertent selection errors. Despite these procedural lapses, the company's financial performance for Q2 FY26 shows a significant recovery, with revenue growing to ₹1,653.47 crore from ₹1,223.70 crore YoY. Net profit surged to ₹194.49 crore compared to just ₹19.95 crore in the previous year's corresponding quarter. The company has also confirmed an interim dividend of ₹0.80 per share.
Key Highlights
Revenue from operations increased 35% YoY to ₹1,653.47 crore for the quarter ended September 30, 2025
Net profit witnessed a massive jump to ₹194.49 crore in Q2 FY26 from ₹19.95 crore in Q2 FY25
Board approved an interim dividend of ₹0.80 per equity share (40% of face value) for FY 2025-26
Company rectified XBRL filing discrepancies and submitted revised machine-readable financial results
H1 FY26 total income reached ₹3,260.43 crore, a significant rise from ₹2,425.72 crore in H1 FY25
👀 What to Watch
Investors should view the regulatory clarification as a resolution of minor procedural issues. The core focus remains on the company's strong earnings turnaround and significant profit growth, which supports a positive long-term outlook.
Laurus Labs Receives NCLT Approval for Subsidiary Restructuring and Amalgamation
Laurus Labs has received approval from the NCLT Amravati Bench for its Composite Scheme of Arrangement involving two wholly-owned subsidiaries. The plan involves demerging Unit-1 of Laurus Synthesis Private Limited (LSPL) into Sriam Labs and merging the remaining LSPL business directly into Laurus Labs Limited. The NCLT has dispensed with meetings for shareholders and creditors of the parent company, significantly streamlining the regulatory path. Meetings for unsecured creditors of the subsidiaries are now scheduled for April 06, 2026, to move the process toward final completion.
Key Highlights
NCLT Amravati Bench allowed the First Motion Application for the scheme on February 24, 2026
Unit-1 of Laurus Synthesis Private Limited to be demerged and merged into Sriam Labs Private Limited
Remaining business undertakings of LSPL to be amalgamated with the parent company, Laurus Labs Limited
Meetings of Equity Shareholders and all Creditors of the parent company (Laurus Labs) have been dispensed with
Meetings for Unsecured Creditors of LSPL and Sriam Labs are directed to be held on April 06, 2026
👀 What to Watch
Investors should view this as a positive step toward corporate simplification and operational efficiency. Monitor the outcome of the unsecured creditor meetings in April as the final steps toward full integration of the CDMO business.
Laurus Labs Q3 FY26 Revenue Up 26% to ₹1,778 Cr; EBITDA Margins Expand to 27%
Laurus Labs reported a strong Q3 FY26 with revenue growing 26% YoY to ₹1,778 crores, driven by a 37% surge in the generics division. Profitability showed significant improvement as EBITDA margins expanded to 27% and PAT for the 9-month period jumped 388% to ₹610 crores. The company is aggressively investing in high-growth areas like peptides and ADCs, with a planned CAPEX of ₹1,000 crores for both FY26 and FY27. Management maintains a healthy balance sheet with a net debt-to-EBITDA ratio of 1.2x.
Key Highlights
Q3 FY26 Revenue grew 26% YoY to ₹1,778 crores with Gross Margins expanding to 60.9%
Generics division revenue rose 37% to ₹1,327 crores, fueled by ARV volumes and new launches
CDMO segment recorded over 50% growth in the 9-month period, despite a phased Q3 performance of ₹408 crores
Planned CAPEX of ₹1,000 crores for FY26 and FY27 to scale peptide and ADC capabilities
9-month PAT surged 388% YoY to ₹610 crores, with ROCE improving to 18.5%
👀 What to Watch
Investors should view the margin expansion and strong CDMO growth as positive indicators of a structural shift in the business mix. Monitor the execution of the new fermentation and ADC facilities for long-term value creation.
Laurus Labs Q3 Net Profit Surges 174% YoY to ₹252 Cr; EBITDA Margins Expand to 27.3%
Laurus Labs reported a robust Q3 FY26 with revenue growing 26% YoY to ₹1,778 crore, driven by a 37% surge in the Generics division. Profitability saw a massive jump, with Net Profit increasing 174% to ₹252 crore and EBITDA margins expanding by 720 bps to 27.3%. For the 9M FY26 period, the company crossed the ₹5,000 crore revenue mark with a 104% growth in EBITDA. While the CDMO segment showed 43% growth in the 9M period, the Bio segment faced temporary scale-up challenges with a 9% decline.
Key Highlights
Q3 FY26 Net Profit grew 174% YoY to ₹252 Cr, while 9M FY26 Net Profit surged 388% to ₹610 Cr
EBITDA margins improved significantly to 27.3% in Q3, up from 20.1% in the previous year
9M FY26 Revenues reached ₹5,001 Cr (+30% YoY), supported by strong performance in CDMO and Generics
Net Debt leverage improved to 1.2x EBITDA despite ongoing CAPEX at 15% of sales
Generics division revenue grew 37% in Q3, led by higher ARV volumes and developed market offtake
👀 What to Watch
Investors should focus on the significant margin expansion and debt reduction as signs of high operational efficiency. The strong 9M performance and the company's strategic shift toward high-value CDMO projects and Peptides/ADC platforms provide a positive long-term outlook.
Laurus Labs Q3 FY26 Net Profit Surges 174% to ₹252 Cr; 9M Revenue Hits ₹5,001 Cr
Laurus Labs reported a robust performance for 9M FY26, with revenues growing 30% YoY to ₹5,001 crore and net profit jumping 388% to ₹610 crore. The growth was primarily driven by the CDMO division, which saw 43% growth in the nine-month period, and strong execution in the Generics segment. EBITDA margins expanded significantly to 26.1% for 9M FY26, up from 16.6% in the previous year, aided by a better product mix and operational leverage. The company continues its aggressive CAPEX plan, investing ₹735 crore in 9M FY26 towards new technologies like peptides and gene therapy.
Key Highlights
9M FY26 Revenue grew 30% YoY to ₹5,001 Cr, while Net Profit skyrocketed 388% to ₹610 Cr.
EBITDA margins improved by 950 bps to 26.1% in 9M FY26 due to better product mix and scale.
CDMO Small Molecules segment grew 50% in 9M FY26, despite a muted Q3 due to campaign timing.
Net Debt-to-EBITDA significantly reduced to 1.2x from 3.1x a year ago, showing improved financial health.
Cumulative CAPEX for FY22-26 is projected at ~₹3,900 Cr, focusing on high-growth areas like Peptides and ADCs.
👀 What to Watch
Investors should take note of the significant margin expansion and the sharp reduction in leverage, which indicate a strong operational turnaround. The company's transition towards high-value CDMO projects and new modalities like gene therapy provides a positive long-term outlook.
